Prostate-specific membrane antigen (PSMA)–targeting radiopharmaceuticals have recently been included in the National Comprehensive Cancer Network, the American Society of Clinical Oncology guidelines, and the European guidelines for prostate cancer detection and selection for radiopharmaceutical therapy with PSMA-targeted agents, such as 177Lu-PSMA-617 (2–4). Here, FOLH1 is linked to prostate carcinoma.